Research Papers:

MicroRNA-107-5p suppresses non-small cell lung cancer by directly targeting oncogene epidermal growth factor receptor

Ping Wang, Xiaomin Liu, Yang Shao, Huimin Wang, Chen Liang, Baohui Han _ and Zhongliang Ma

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:57012-57023. https://doi.org/10.18632/oncotarget.18505

Metrics: PDF 1391 views  |   HTML 2157 views  |   ?  


Ping Wang1,*, Xiaomin Liu1,*, Yang Shao1,2, Huimin Wang1, Chen Liang1, Baohui Han3 and Zhongliang Ma1

1Laboratory for Noncoding RNA & Cancer, School of Life Sciences, Shanghai University, Shanghai, China

2Cancer Institute, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

3Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China

*These authors have contributed equally to this work

Correspondence to:

Baohui Han, email: [email protected]

Zhongliang Ma, email: [email protected]

Keywords: MicroRNA-107-5p, EGFR, NSCLC, tumorigenesis, proliferation

Received: March 17, 2017    Accepted: April 25, 2017    Published: June 16, 2017


MicroRNAs (miRNAs) are dysregulated in cancers, including human non-small cell lung cancer (NSCLC). The function of MicroRNA-107-5p (miR-107-5p) in NSCLC is not fully elucidated. Epidermal growth factor receptor (EGFR) is a cancer-driven gene in tumorigenesis. In this study, we found that miR-107-5p was significantly decreased in NSCLC tissues and NSCLC cell lines. Moreover, our results indicated that miR-107-5p could suppress cell proliferation, inhibit metastasis, impede cell cycle, and promote apoptosis via directly targeting EGFR. We also investigated roles of miR-107-5p in vivo. The results showed that it could inhibit tumor growth. Therefore, our study demonstrated that miR-107-5p not only suppressed the progression in NSCLC cells by inhibiting the expression of EGFR, but also could be a promising and a new potential therapeutic target for lung cancer.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18505